SinuGeniX is an emerging medical device company focused on commercializing a product family, with initial focus on its patented RegENTâ„¢ System, the next generation of balloon dilation sinuplasty (BDS) for the treatment of chronic rhinosinusitis (CRS), which affects approximately 35 million people annually in the U.S.  CRS is responsible for more than $8 billion in direct costs annually to the U.S. healthcare system.